Market Place
Sourcing Support
Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2
30 Oct 2025 //
BUSINESSWIRE
Iambic Collaborates With Jazz Pharma On Her2+ Breast Cancer Study
21 Oct 2025 //
BUSINESSWIRE
ESMO: Daiichi, Merck Move Ovarian Cancer ADC Toward Pivotal Test
20 Oct 2025 //
FIERCE BIOTECH
Datroway Shows 5-Month Survival Gain Over Chemotherapy
19 Oct 2025 //
BUSINESSWIRE
Enhertu+THP Yields 67% pCR in High-Risk HER2+ Breast Cancer
18 Oct 2025 //
BUSINESSWIRE
Enhertu Cuts Recurrence or Death Risk by 53% in Ph3 Breast Trial
18 Oct 2025 //
BUSINESSWIRE
ENHERTU® Preceded By THP Yields 67% Pathologic Response
18 Oct 2025 //
BUSINESSWIRE
Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer
18 Oct 2025 //
BUSINESSWIRE
Datroway`s Rilvegostomig Show Promise Result in Urothelial Cancer
17 Oct 2025 //
BUSINESSWIRE
Merck Advances Oncology Innovation At ESMO 2025
09 Oct 2025 //
PHARMIWEB
Astrazeneca Pharma India Gets CDSCO Approval For Trastuzumab
04 Oct 2025 //
INDPHARMAPOST
ENHERTU THP Combo BLA Accepted for High-Risk HER2+ Breast Cancer
01 Oct 2025 //
BUSINESSWIRE
ENHERTU Shows iDFS Benefit in High-Risk Early Breast Cancer
29 Sep 2025 //
BUSINESSWIRE
ENHERTU + Pertuzumab Gets US Priority Review In 1L HER2+ Cancer
24 Sep 2025 //
BUSINESSWIRE
FDA Grants BTD To R-DXd For Platinum-Resistant Ovarian Cancers
16 Sep 2025 //
INDPHARMAPOST
FDA Grants Breakthrough Tag to Raludotatug Deruxtecan in CDH6
15 Sep 2025 //
BUSINESSWIRE
Daiichi, Merck Prepare for Swift Approval Filing
07 Sep 2025 //
FIERCE BIOTECH
Daiichi Sankyo`s Ifinatamab Deruxtecan Shows Promising Response
07 Sep 2025 //
BUSINESSWIRE
Daiichi, Merck pull HER3-DXd filing at FDA
29 May 2025 //
REUTERS
Alligator Bioscience starts HLX22 Phase 2 trial in breast cancer
23 Apr 2025 //
ACCESSWIRE
Enhertu drives strong efficacy in first-line breast cancer
22 Apr 2025 //
BUSINESSWIRE
ENHERTU® Phase 3 Trial Begins for HER2+ Advanced Gastric Cancer
01 Apr 2025 //
BUSINESSWIRE
Datopotamab Shows Clinical Activity in EGFR-Mutated Lung Cancer
05 Dec 2024 //
BUSINESSWIRE
Merck, Daiichi`s ADC Lung Cancer Trial Shows Promise Despite Deaths
18 Sep 2024 //
BUSINESSWIRE
ENHERTU Shows Activity In HER2+ Breast Cancer With Brain Metastases
13 Sep 2024 //
BUSINESSWIRE
Ifinatamab Deruxtecan Shows Promise In Small Cell Lung Cancer Trial
07 Sep 2024 //
BUSINESSWIRE
First Patient Dosed In IDeate-Lung02 Trial Of Ifinatamab Deruxtecan
03 Aug 2024 //
PHARMABIZ
IDeate-Lung02 Phase 3 Trial Of Ifinatamab Deruxtecan Initiated
01 Aug 2024 //
BUSINESSWIRE
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter From FDA
26 Jun 2024 //
BUSINESSWIRE
Tropion-Lung01: Nsclc Vs Chemo Clinically Meaningful Improvement
27 May 2024 //
BUSINESSWIRE
AstraZeneca, Daiichi aim for first pan-tumor ADC approval
30 Jan 2024 //
BIOPHARMADIVE
ENHERTU granted Priority Review for patients with HER2-positive solid tumors
29 Jan 2024 //
BUSINESSWIRE
Enhertu granted Priority Review in the US for patients with solid tumours
29 Jan 2024 //
PRESS RELEASE
Seagen patent invalidated in long-running Daiichi Sankyo spat
18 Jan 2024 //
FIERCE PHARMA
After Enhertu success, Daiichi and AstraZeneca branch off
25 Oct 2023 //
FIERCE BIOTECH
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for NSCLC
23 Oct 2023 //
BUSINESSWIRE
ENHERTU Demonstrated Survival Across Multiple HER2 Expressing Solid Tumors
23 Oct 2023 //
BUSINESSWIRE
AstraZeneca-Daiichi get some clarity on Enhertu follow up med
23 Oct 2023 //
FIERCE BIOTECH
NICE poised to reject Enhertu in HER2-low breast cancer
28 Sep 2023 //
FIERCE PHARMA
CHMP recommends AstraZeneca, Daiichi`s Enhertu for HER2-mutant NSCLC
16 Sep 2023 //
PRESS RELEASE
ENHERTU Shows Strong Responses in Treated HER2-mutant Advanced Lung Cancer
11 Sep 2023 //
BUSINESSWIRE
BioNTech, DualityBio steer ADC into PhIII with Enhertu
01 Sep 2023 //
#N/A
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients
31 Aug 2023 //
BUSINESSWIRE
Enhertu wins two FDA breakthrough therapy designations
31 Aug 2023 //
PHARMACEUTICAL TECHNOLOGY
FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan
31 Aug 2023 //
ONCLIVE
Trastuzumab Deruxtecan Approved in Japan for HER2-Mutated Metastatic NSCLC
23 Aug 2023 //
ONCLIVE
Enhertu Shows OS across multiple HER2-expressing advanced solid tumours in PII
27 Jul 2023 //
PRESS RELEASE
Expanding Definitions of HER2 Expression Mediate Role of ADCs in Breast Cancer
26 Jul 2023 //
ONCLIVE
Enhertu gains more Chinese momentum with HER2-low breast cancer approval
13 Jul 2023 //
PRESS RELEASE
Enhertu shows 37.1% response rate in HER2-expressing solid tumours
06 Jun 2023 //
BUSINESSWIRE
Daiichi Sankyo to showcase latest research towards creating new standards care
27 May 2023 //
PHARMABIZ
AstraZeneca Pharma India receives DCGI’s approval for import of cancer drug
03 May 2023 //
THEHINDUBUSINESSLINE
AZ, Daiichi`s Enhertu posts trial win in numerous cancer types
07 Mar 2023 //
FIERCE PHARMA
ENHERTU Showed Durable Responses Across Multiple HER2-expressing Tumor
06 Mar 2023 //
BUSINESSWIRE
New Ambrx CEO spies a path for ousted breast cancer med
01 Mar 2023 //
FIERCE BIOTECH
Trastuzumab Deruxtecan Garners Approval for HER2+ Metastatic Breast Cancer
25 Feb 2023 //
PRESS RELEASE
Enhertu approved in Europe for HER2-low metastatic breast cancer
27 Jan 2023 //
PRESS RELEASE
ENHERTU Type II Variation Application Validated by EMA for HER2 NSCLC
04 Jan 2023 //
BUSINESSWIRE
Enhertu recommended for approval in EU by CHMP for patients with breast cancer
19 Dec 2022 //
PRESS RELEASE
